Recently, in search for alternative therapeutic targets for advanced cancer, RORγ in tumor cells was identified to play a critical role in tumor progression in certain types of cancer (Zou et al., 2022a), including castration-resistant prostate cancer (CRPC) (Wang et al., 2016; Wang et al., 2020; Zheng et al., 2020; Zhang et al., 2021), triple-negative breast cancer (TNBC) (Cai et al., 2019; Zou et al., 2022b), small cell lung carcinoma (SCLC) (Chen et al., 2022) and pancreatic ductal adenocarcinoma (PDAC) (Lytle et al., 2019). The gene discussed is RORC; the disease is triple-negative breast carcinoma.